The barrier function of CYP3A4 and P-glycoprotein in the small bowel

Advanced Drug Delivery Reviews

Volumn 27, Issue 2-3, 1997, Pages 161-170

  Watkins, Paul B ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Bioavailability; CYP3A4; Cytochrome P450; Drug metabolism; Drug transport; Human small intestine; P glycoprot@in

Indexed keywords

ABSORPTION; CATALYSIS; METABOLISM; PROTEINS; SUBSTRATES;

CYTOCHROME P450; HUMAN SMALL INTESTINE; ORAL BIOAVAILABILITY; P GLYCOPROTEIN;

DRUG INTERACTIONS;

CYCLOSPORIN; CYTOCHROME P450 ISOENZYME; GLYCOPROTEIN P;

CELL STRAIN CACO 2; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG TRANSPORT; FIRST PASS EFFECT; HUMAN; INTESTINE ABSORPTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SMALL INTESTINE; SWINE;

EID: 0342762062     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(97)00041-0     Document Type: Review

References (59)

1. Watkins P.B., Wrighton S.A., Schuetz E.G., Molowa D.T., Guzelian P.S. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J. Clin. Invest. 80:1987;1029-1036.
2. Kolars J.C., Schmiedlin-Ren P., Schuetz J.D., Fang C., Watkins P.B. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest. 90:1992;1871-1878.
3. Paine M.F., Shen D.D., Kunze K.L., Perkins J.D., Marsh C.L., McVicar J.P., Barr D.M., Gillies B.S., Thummel K.E. First-pass metabolism of midazolam by the human intestine. Clin. Pharmacol. Ther. 60:1996;14-24.
4. Fitzsimmons F.E., Collins J.M. Selective biotransformation of the HIV protease inhibitor saquinavir by human small intestinal cytochrome P450 3A4. Drug Metab. Dispos. 25:1997;256-266.
5. de Lannoy I.A.M., Silverman M. The MDR1 gene product, P-glycoprotein, mediates the transport of cardiac glycoside, digoxin. Biochem. Biophys. Res. Commun. 189:1992;551-557.
6. Kolars J.C., Awni W.M., Merion R.M., Watkins P.B. First-pass metabolism of cyclosporin by the gut. Lancet. 338:1991;1488-1490.
7. Lown K.S., Kolars J.C., Thummel K.E., Barnett J.L., Kunze K.L., Wrighton S.A., Watkins P.B. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test [published erratum appears in Drug Metab. Dispos. (1995) 23(3), following the table of contents]. Drug Metab. Dispos. 22:1994;947-955.
8. Janardan S.K., Lown K.S., Ghosh M., Kolars J.C., Watkins P.B. CYP3A5 expression in human enterocytes. Gastroenterology. 106(4):1994;A241.
9. Kivisto K.T., Bookjans G., Fromm M.F., Griese E.-U., Munzel P., Kroemer H.K. Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Br. J. Clin. Pharmacol. 42:1996;387-389.
10. Kolars J.C., Lown K.S., Schmiedlin-Ren P., Ghosh M., Fang C., Wrighton S.A., Merion R.M., Watkins P.B. CYP3A gene expression in human gut epithelium. Pharmacogenetics. 4:1994;247-259.
11. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann. Rev. Biochem. 62:1993;385-427.
12. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U.S.A. 84:1987;7735-7738.
13. Hsing S., Gatmaitan Z., Arias I.M. The function of Gp170, the multidrug-resistance gene product, in the brush border of rat intestinal mucosa. Gastroenterology. 102:1992;879-885.
14. K.S. Lown, R. Mayo, D.S. Blake, L.Z. Benet, P.B. Watkins, Interpatient variation in intestinal Pgp expression contributes to variable oral kinetics of cyclosporin A, Clin. Pharmacol. Ther. (1997) in press.
15. H.C. Lin, J.H. Meyer, Disorders of gastric emptying, in: T. Yamada (Ed.), Textbook of Gastroenterology, Lippincott, New York, 1991, pp. 1215-1230.
16. Hunter J., Hirst B.H., Simmons N.L. Epithelial secretion of vinblastine by human intestinal adenocarcinoma cell (hct-8 and t84) layers expressing p-glycoprotein. Br. J. Cancer. 64:1991;437-444.
17. Hunter J., Jepson M.A., Tsuruo T., Simmons N.L., Hirst B.H. Functional expression of p-glycoprotein in apical membranes of human intestinal Caco-2 cells: kinetics of vinblastine secretion and interaction with modulators. J. Biol. Chem. 268:1993;14991-14997.
18. Hunter J., Hirst B.H., Simmons N.L. Drug absorption limited by p-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm. Res. 10:1993;743-749.
19. Saitoh H., Aungst B.J. Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharm. Res. 12:1995;1304-1310.
20. Augustijns P.F., Bradshaw T.P., Gan L.-S.L., Hendren R.W., Thakker D.R. Evidence for a polarized efflux system in Caco-2 cells capable of modulating cyclosporin A transport. Biochem. Biophys. Res. Commun. 197:1993;360-364.
21. Karlsson J., Kuo S.-M., Ziemniak J., Artursson P. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including p-glycoprotein. Br. J. Pharm. 110:1993;1009-1016.
22. Burton P.S., Conradi R.A., Hilgers A.R., Ho N.F.H. Evidence for a polarized efflux system for peptides in the apical membrane of Caco-2 cells. Biochem. Biophys. Res. Commun. 190:1993;760-766.
23. Chikhale E.G., Burton P.S., Borchardt R.T. The effect of verapamil on the transport of peptides across the blood-brain barrier in rats: kinetic evidence for an apically polarized efflux mechanism. J. Pharmacol. Exp. Ther. 273:1995;298-303.
24. Caldwell J.H., Caldwell P.B., Murphy J.W., Beachler C.W. Intestinal secretion of digoxin in the rat. Arch. Pharm. 312:1980;271-275.
25. Gramatte T., Oertel R., Terhaag B., Kirch W. Direct demonstration of small intestinal secretion and site-dependent absorption of the beta blocker talinolol in humans. Clin. Pharmacol. Ther. 59:1996;541-549.
26. Rabbaa L., Dautrey S., Colas-Linhart N., Carbon C., Farinotti R. Intestinal elimination of ofloxacin enantiomers in the rat: evidence of a carrier-mediated process. Antimicrob. Agents Chemother. 40:1996;2126-2130.
27. Ramon J., Dautrey S., Farinoti R., Carbon C., Rubinstein E. Intestinal elimination of ciprofloxacin in rabbits. Antimicrob. Agents Chemother. 38:1994;757-760.
28. Rubinstein E., St. Julien L., Ramon J., Dautrey S., Farinotti R., Huneau J.-F., Carbon C. The intestinal elimination of ciprofloxacin in the rat. J. Infect. Dis. 169:1994;218-221.
29. Griffiths N.M., Hirst B.H., Simmons N.L. Active intestinal secretion of the fluoroquinolone antibacterials ciprofloxacin, norfloxacin and pefloxacin; a common secretory pathway? J. Pharmacol. Exp. Ther. 269:1994;496-502.
30. Tsuji A., Tamai I., Sakata A., Tenda Y., Terasaki T. Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter, P-glycoprotein. Biochem. Pharmacol. 46:1993;1096-1099.
31. Leu B.-L., Huang J. Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother. Pharmacol. 35:1995;432-436.
32. Tsuji A., Tamai I. Carrier-mediated intestinal transport of drugs. Pharm. Res. 13:1996;963-977.
33. Gan L.-S.L., Moseley A., Khosla B., Augustijns P.F., Bradshaw T.P., Hendren R.W., Thakker D.R. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Interaction between the two biochemical barriers to intestinal transport. Drug Metab. Dispos. 24:1996;344-349.
34. 3. Mol. Pharmacol. 51:1997;741-754.
35. Evers R., Zaman G.J.R., van Deemter L., Jansen H., Calafat J., Oomen J.C.J.M., Elferink R.P.J.O., Borst P., Schinkel A.H. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J. Clin. Invest. 97:1996;1211-1218.
36. Spaldin V., Madden S., Adams D.A., Edwards R.J., Davies D.S., Park B.K. Determination of human hepatic cytochrome P4501A2 activity in vitro. Use of tacrine as an isoenzyme-specific probe. Drug Metab. Dispos. 23:1995;929-934.
37. Lown K.S., Kolars J.C., Ghosh M., Schmiedlin-Ren P., Watkins P.B. Induction of MDR1 expression in normal rat and human intestine in vivo. Gastroenterology. 110:1996;A344.
38. Watkins P.B., Murray S.A., Winkelman L.G., Heuman D.M., Wrighton S.A., Guzelian P.S. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J. Clin. Invest. 83:1989;688-697.
39. Hebert M.F., Roberts J.P., Prueksaritanont T., Benet L.Z. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin. Pharmacol. Ther. 52:1992;453-457.
40. Hebert M.F., Roberts J.P., Prueksaritanont T., Benet L.Z. Bioavailablity of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin. Pharmacol. Ther. 52:1992;453-457.
41. Wu C.Y., Benet L.Z., Hebert M.F., Gupta S.K., Rowland M., Gomez D.Y., Wacher V.J. Differentiation of absorption and first pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin. Pharmacol. Ther. 58:1995;492-497.
42. Benet L.Z., Wu C.-Y., Hebert M.F., Wacher V.J. Intestinal drug metabolism and antitransport processes: a potential paradigm shift in oral drug delivery. J. Control. Release. 39:1996;139-143.
43. Wacher V.J., Wu C.Y., Benet L.Z. Overlapping substrate specificities and tissue distribution of cytochrome P4503A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 13:1995;129-134.
44. Schuetz E.G., Furuya K.N., Schuetz J.D. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J. Pharmacol. Exp. Ther. 275:1995;1011-1018.
45. Kronbach T., Fischer V., Meyer U.A. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin. Pharmacol. Ther. 43:1988;630-635.
46. Saeki T., Ueda K., Tanigawara Y., Hori R., Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem. 268:1993;6077-6080.
47. Kolars J.C., Schmiedlin-Ren P., Dobbins III W.O., Schuetz J., Wrighton S.A., Watkins P.B. Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia. Gastroenterology. 102:1992;1186-1198.
48. Schuetz E.G., Beck W.T., Schuetz J.D. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol. Pharmacol. 49:1996;311-318.
49. Lown K.S., Bailey D., Fontana R., Janardan S., Adair C.H., Fortlage L.A., Brown M.B., Guo W., Watkins P.B. Grapefruit juice increases felodipine oral availability in man by decreasing intestinal CYP3A protein expression. J. Clin. Invest. 99:1997;2545-2553.
50. Kolars J.C., Stetson P.L., Rush B.D., Ruwart M.J., Schmiedlin-Ren P., Duell E.A., Voorhees J.J., Watkins P.B. Cyclosporine metabolism by P450IIIA in rat enterocytes - another determinant of oral bioavailability? Transplantation. 53:1992;596-602.
51. Gan L.S., Moseley A., Khosla B., Augustijns P., Bradshaw T., Hendren W., Thakker D. Formation and polarized efflux of cyclosporin A metabolites in the in vitro Caco-2 cell culture system. FASEB J. 9:1995;A367.
52. Waziers D.E., Cugnenc P.H., Yang C.S., Leroux J.-P., Beaune P.H. Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J. Pharmacol. Exp. Ther. 253:1989;387-394.
53. Homsy W., Caille G., duSouich P. The site of absorption in the small intestine determines diltiazem bioavailability in the rabbit. Pharm. Res. 12:1995;1722-1726.
54. Marathe P.H., Salazar D.E., Greene D.S., Brennan J., Shukla U.A., Barbhaiya R.H. Absorption and presystemic metabolism of nefazodone administered at different regions in the gastrointestinal tract of humans. Pharm. Res. 12:1995;1716-1721.
55. 12C nifedipine. Eur. J. Clin. Pharmacol. 50:1996;195-201.
56. Trezise A.E.O., Romano P.R., Gill D.R., Hyde S.C., Sepulveda F.V., Buchwald M., Higgins C.F. The multidrug resistance and cystic fibrosis genes have complementary patterns of epithelial expression. EMBO J. 11:1992;4291-4303.
57. Christians U., Sewing K.F. Cyclosporin metabolism in transplant patients. Pharmacol. Ther. 57:1993;291-345.
58. Carriere V., Lesuffleur T., Barbat A., Rousset M., Dussaulx E., Costet P., deWaziers I., Beaune P., Zweibaum A. Expression of cytochrome P-450 3A in ht29-mtx cells and Caco-2 clone tc7. FEBS Lett. 355:1994;247-250.
59. Crespi C.L., Penman B.W., Hu M. The development of Caco-2 cells expressing high levels of cDNA-derived cytochrome P450 3A4. Pharm. Res. 13:1996;1635-1641.